

Amino Acid Residues in Transmembrane Domain 10 of Organic Anion Transporting Polypeptide 1B3 Are Critical for Cholecystokinin Octapeptide Transport[†]

Chunshan Gui[‡] and Bruno Hagenbuch^{*,‡,§}

Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas 66160, and Kansas Masonic Cancer Research Institute, The University of Kansas Medical Center, Kansas City, Kansas 66160

Received May 8, 2008; Revised Manuscript Received July 10, 2008

ABSTRACT: Human organic anion transporting polypeptides (OATP) 1B1 and 1B3 are multispecific transporters that mediate uptake of amphipathic organic compounds into hepatocytes. The two OATPs contain 12 transmembrane domains (TMs) and share 80% amino acid sequence identity. Besides common substrates with OATP1B1, OATP1B3 specifically transports cholecystokinin octapeptide (CCK-8). To determine which structural domains and/or residues are important for the substrate selectivity of OATP1B3, we constructed a series of chimeric proteins between OATP1B3 and 1B1, expressed them in HEK293 cells, and determined rates of uptake of CCK-8 along with surface expression of the proteins. Replacing TM10 in OATP1B3 with TM10 of OATP1B1 resulted in a dramatically reduced degree of CCK-8 transport, indicating that TM10 is crucial for recognition and/or translocation of CCK-8. Using site-directed mutagenesis, we identified three key residues within TM10, namely, Y537, S545, and T550. When we replaced these residues with the corresponding amino acid residues found in OATP1B1, the level of CCK-8 transport was similarly low as for the replacement of the whole TM10. Kinetic experiments showed that the K_m values for CCK-8 transport in the TM10 replacement and triple mutant were only 1.3 and 1.1 μM , respectively, as compared to 16.3 μM for wild-type OATP1B3. Similarly, the V_{max} values dropped from 495.5 pmol (normalized mg)^{−1} min^{−1} for wild-type OATP1B3 to 13.3 and 19.0 pmol (normalized mg)^{−1} min^{−1} for the TM10 replacement and triple mutant, respectively. Molecular modeling indicated that two of the three identified residues might form hydrogen bonds with CCK-8. In conclusion, we have identified three amino acid residues (Y537, S545, and T550) in TM10 of OATP1B3 that are important for CCK-8 transport.

The mammalian liver is the major detoxification organ of the body, and the hepatic sinusoidal membrane is equipped with transporters that mediate influx and efflux of endogenous and xenobiotic compounds. Uptake transporters belong to the superfamily of solute carriers (SLCs)¹ (1) which mediate the first step of the hepatic elimination by facilitating hepatic uptake of those compounds from the portal vein. In humans, organic anion transporting polypeptides (OATPs, gene symbol *SLCO*) mediate the sodium-independent transport of a wide range of amphipathic organic compounds, including numerous drugs and other xenobiotics (2). There are 11 human OATPs (3, 4) with the polyspecific OATP1B3

and 1B1 being predominantly expressed at the basolateral membrane of hepatocytes (5–9), indicating their significant roles in the hepatic clearance of amphipathic organic compounds. OATP1B3 shares 80% amino acid sequence identity with OATP1B1. Recent findings for rat *Oatp1a1* suggest that all OATPs comprise 12 putative transmembrane domains (TMs) (10). As expected from their high degree of sequence similarity, OATP1B3 and 1B1 exhibit overlapping transport activities for an array of substances, including bile salts, unconjugated and conjugated bilirubin, bromosulphothalein (BSP), steroid conjugates, thyroid hormones, eicosanoids, peptides, drugs, and the natural toxins phalloidin and microcystin (4).

Although OATP1B3 shares a great number of substrates with OATP1B1, it also possesses its own specific substrates. OATP1B3 selectively transports cholecystokinin octapeptide (CCK-8), the anticancer drugs paclitaxel and docetaxel, and the cardiac glycosides digoxin and ouabain (11–13). So far, little is known about the molecular mechanism for substrate selectivity of OATP1B3. Therefore, in this study, we focused on delineating the structural domains and molecular determinants responsible for CCK-8 transport of OATP1B3 by constructing a series of OATP1B1/1B3 chimeric transporters,

[†] This work was supported by National Institutes of Health Grants RR021940 and GM077336.

* To whom correspondence should be addressed: Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160. Phone: (913) 588-0028. Fax: (913) 588-7501. E-mail: bhagenbuch@kumc.edu.

[‡] Department of Pharmacology, Toxicology and Therapeutics.

[§] Kansas Masonic Cancer Research Institute.

¹ Abbreviations: BSP, bromosulphothalein; CCK-8, cholecystokinin octapeptide; DHEAS, dehydroepiandrosterone 3-sulfate; DPDPE, [D-penicillamine²⁻⁵]enkephalin; EL, extracellular loop; HEK293, human embryonic kidney cells; OATP, organic anion transporting polypeptide; PBS, phosphate-buffered saline; SLC, solute carrier; TM, transmembrane domain.

performing site-directed mutagenesis, characterizing CCK-8 transport, and constructing a molecular model.

EXPERIMENTAL PROCEDURES

Chemicals and Reagents. Radiolabeled [^3H]CCK-8 (92 Ci/mmol) was purchased from Amersham Biosciences (Piscataway, NJ), and unlabeled CCK-8 was obtained from Sigma-Aldrich (St. Louis, MO). Cell culture reagents, Lipofectamine 2000, and the pcDNA5/FRT vector were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum was obtained from Hyclone (Logan, UT). The QuikChange site-directed mutagenesis kit was from Stratagene (La Jolla, CA). Sulfo-*N*-hydroxysuccinimide-SS-biotin, streptavidin-agarose beads, and the BCA protein assay kit were from Pierce Chemical (Rockford, IL). Antibodies for detecting the His tag and the Na^+/K^+ -ATPase α subunit were purchased from Covance (Princeton, NJ) and Abcam (Boston, MA). Poly-D-lysine was purchased from Sigma-Aldrich. The protease inhibitor cocktail was from Roche (Indianapolis, IN), and the enhanced chemiluminescence (ECL) plus Western blotting detection kit was from Amersham Biosciences.

Construction of Chimeric Transporters and Mutants. A six-His tag was introduced at the C-terminal end of the open reading frames of human OATP1B1*1b (14) and OATP1B3 haplotype 1 (15) by PCR, and the resulting constructs were cloned into the pcDNA5/FRT vector (Invitrogen) using *NheI* and *NotI* sites. To construct chimeric transporters of OATP1B1 and 1B3, the junction sites were determined on the basis of the topological structures of OATP1B1 and 1B3 predicted by TMPred (http://www.ch.embnet.org/software/TMPRED_form.html), and overlapping PCR was employed. The lengths of overlapping regions were 20–23 bases. For site-directed mutagenesis, mutants were generated using the QuikChange kit (Stratagene). The sequences of all constructs were confirmed by DNA sequencing.

Protein Expression in HEK293 Cells. Human embryonic kidney (HEK293) cells were grown at 37 °C in a humidified 5% CO_2 atmosphere in Dulbecco's modified Eagle's medium, containing 4.5 g/L D-glucose, 2 mM L-glutamine, 25 mM Hepes buffer, and 110 mg/L sodium pyruvate, supplemented with 10% FBS, 100 units/mL penicillin, and 100 $\mu\text{g}/\text{mL}$ streptomycin. Plasmids containing OATP1B1, OATP1B3, and their chimeric constructs were transiently transfected into HEK293 cells using Lipofectamine 2000 according to the manufacturer's instructions. Transfected cells were incubated for 48 h at 37 °C and then used for protein surface expression and transport assays.

Cell Surface Biotinylation and Immunoblot Analysis. HEK293 cells were grown in poly-D-lysine-coated six-well plates and transfected as described above. Biotinylation experiments were conducted 48 h post-transfection. Cells were washed twice with 2 mL of ice-cold phosphate-buffered saline (PBS) and then treated with 1 mL of sulfo-*N*-hydroxysuccinimide-SS-biotin (1 mg/mL in PBS) for 1 h at 4 °C. Then, cells were washed three times with 2 mL of ice-cold PBS containing 100 mM glycine and incubated for 10 min at 4 °C with the same buffer. After being washed with PBS three times, cells were lysed with 700 μL of lysis buffer [10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, and 1% Triton X-100 (pH 7.4) containing protease inhibitors (Roche)] for 1 h at 4 °C with shaking. Lysates

were centrifuged at 10000g for 2 min. Supernatants were incubated with 140 μL of streptavidin-agarose beads for 1 h at room temperature with constant agitation. Beads were then pelleted at 850g for 1 min and washed three times with ice-cold lysis buffer. Cell surface proteins were recovered from the resin by incubation of the beads with 150 μL of 2 \times Laemmli buffer containing 100 mM dithiothreitol at room temperature for 30 min. Cell membrane proteins were subjected to SDS-polyacrylamide gel electrophoresis and immunoblot analysis. OATP1B1, 1B3, and chimeric proteins were detected with a rabbit anti-His polyclonal antibody (1:2500 dilution), followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (1:10000 dilution). Protein loading was normalized by plasma membrane marker Na^+/K^+ -ATPase detected with mouse anti- Na^+/K^+ -ATPase α subunit antibody (1:5000 dilution). Immunoblots were developed with ECL plus reagent (Amersham Biosciences) and detected with X-ray film. The intensities of the protein bands were quantified using Quantity One (Bio-Rad Laboratories, Hercules, CA).

Functional Studies of Transporters in HEK293 Cells. HEK293 cells were seeded in poly-D-lysine-coated 12-well plates and transfected with lipofectamine. Transport assays were performed 48 h post-transfection. Cells were washed three times with 2 mL of prewarmed uptake buffer [100 mM NaCl, 2 mM KCl, 1 mM CaCl_2 , 1 mM MgCl_2 , and 10 mM Hepes (pH adjusted to 7.4 with Trizma base)], and uptake was started by adding 400 μL of uptake buffer containing radiolabeled substrate. After the incubation, uptake was stopped by removing the uptake solution and washing the cells four times with 2 mL of ice-cold uptake buffer. The cells were then solubilized with 500 μL of 1% Triton X-100, and 300 μL of the lysate was used for liquid scintillation counting (Research Products International Corp.) to quantify the radioactivity. The total protein concentration in each uptake well was measured using a BCA protein assay kit (Pierce), and the rate of uptake in each well was normalized to its total protein concentration. In all studies, cells transfected with empty vector served as the background control. Initial experiments showed that uptake was linear over at least 1 min. Therefore, all uptake and kinetic experiments were performed under these initial linear conditions at 1 min. Transporter-specific uptake was calculated by subtracting the background uptake of vector-transfected cells (in picomoles per milligram of total protein per minute) from uptake of OATP-transfected cells (in picomoles per milligram of total protein per minute). This number then was normalized to OATP1B3 surface expression levels (surface expression of wild-type OATP1B3 was set to 1) and given as picomoles per normalized milligram per minute as follows: $\text{picomoles}/(\text{milligram of total protein} \times \text{normalization ratio})/\text{minute}$, where normalization ratio is the surface expression level_{mutant}/surface expression level_{OATP1B3}.

Structural Modeling of OATP1B3 and Molecular Docking of CCK-8 to OATP1B3. The fold recognition method of mGenTHREADER (16) was used to identify templates to model the structure of OATP1B3. Modeling was performed using the Homology module in InsightII (17). First, the coordinates of the TMs of OATP1B3 were assigned according to the structure of EmrD (PDB entry 2GFP). Then the Loop_Search module was used to model the loop regions between the TMs, and the whole structure was subjected to




FIGURE 1: Schematic representation of human OATP1B1, 1B3, and chimeras T1–6 and T7–12, and their surface expression in HEK293 cells. (A) Chimera T1–6 consisted of TMs 1–6 (residues 1–275) of OATP1B3 and TMs 7–12 (residues 276–691) of OATP1B1, while chimera T7–12 consisted of TMs 1–6 (residues 1–275) of OATP1B1 and TMs 7–12 (residues 276–702) of OATP1B3. To detect all constructs with the same antibody, a His tag was introduced at the C-terminal end of all constructs. (B) Western blot analysis of surface-biotinylated proteins detected with an anti-His antibody. The plasma membrane marker Na⁺/K⁺-ATPase α subunit was used as a protein loading control.

structural optimization with the Auto_Rotamer and Discover modules. The quality of the final model was assessed with several structural analysis programs such as Prostat to check bond lengths, angles, and torsions and Procheck (18) for a stereochemical evaluation.

To identify the potential mode of interaction of CCK-8 with OATP1B3, molecular docking of CCK-8 to the OATP1B3 model was carried out using AutoDock 3.0 (19). The Lamarckian genetic algorithm (LGA) was used for docking with the following settings: a maximum number of 1500000 energy evaluations, an initial population of 50 randomly placed individuals, a maximum number of 37000 generations, a mutation rate of 0.02, a crossover rate of 0.80, and an elitism value (number of top individuals that automatically survive) of 1. For the adaptive local search method, the pseudo-Solis and Wets algorithm was applied with a maximum of 300 iterations per search. The conformer with the lowest binding free energy and reasonable conformation was selected and subjected to a 500-step energy minimization within the binding site of OATP1B3 using Sybyl 7.1 (20), and the obtained conformation was adopted as the final binding conformation of CCK-8 for OATP1B3. The interactions between CCK-8 and OATP1B3 were analyzed with Ligplot (21).

Data Analysis. Uptake experiments were performed in duplicate and repeated two or three times. Data with error bars represent the means \pm the standard deviation. To analyze whether the groups were different from the control, ANOVA was performed followed by the Bonferroni *t*-test with SigmaStat 3.5 (Systat Software, Inc., San Jose, CA). The *p* value for statistical significance was set to <0.05 . The kinetic parameters were obtained by nonlinear regression fitting with the Enzyme Kinetics Module of SigmaPlot (Systat Software).

RESULTS

Characterization of Surface Expression and Function of OATP1B1, OATP1B3, and Chimeric Transporters T1–6 and T7–12. Full-length human OATP1B1 and 1B3 comprise 691 and 702 residues, respectively. They share 80% amino acid

sequence similarity and have 12 TMs with the N- and C-termini located intracellularly (3). Thus, we divided OATP1B1 and 1B3 into N- and C-terminal halves, each half-consisting of six TMs. To determine which half is important for the transport of the OATP1B3-specific substrate CCK-8, we constructed two chimeric transporters. Chimera T1–6 contained the first half of OATP1B3 (residues 1–275) fused to the second half of OATP1B1 (residues 276–691), and chimera T7–12 contained the first half of OATP1B1 (residues 1–275) fused to the second half of OATP1B3 (residues 276–702) (Figure 1A). OATP1B1, 1B3, and the two chimeric transporters were transiently expressed in HEK293 cells. To quantitate surface expression of the two OATPs and the chimeras, we performed Western blot analysis with an anti-His antibody after purifying surface proteins using biotinylation. As a loading control, we used the α subunit of Na⁺/K⁺-ATPase (Figure 1B). The anti-His antibody detected a band at ~ 84 kDa for OATP1B1 and at ~ 120 kDa for OATP1B3 (Figure 1B), which is consistent with the reported molecular masses of their fully glycosylated forms (8, 9). The apparent molecular masses of chimeras T1–6 and T7–12 were ~ 90 and ~ 100 kDa, respectively. Bands with higher molecular masses were also detected for OATP1B1, 1B3, and chimera T1–6 and probably represent multimeric aggregates. The surface expression levels were normalized to OATP1B3 and were 1.04 for OATP1B1, 1.62 for chimera T1–6, and 0.53 for chimera T7–12.

Figure 2 summarizes the functional results that we obtained with the four constructs. The expression system worked well as OATP1B3 had high transport activity for CCK-8 [4.3 pmol (normalized mg)⁻¹ min⁻¹] which was 10-fold higher than that of OATP1B1 [0.4 pmol (normalized mg)⁻¹ min⁻¹]. The activities of chimeras T1–6 and T7–12 decreased significantly compared to OATP1B3 and were 10 and 34% of that of OATP1B3, respectively. These results indicate that both N- and C-terminal halves contribute to OATP1B3-mediated CCK-8 transport with the C-terminal half playing a more important role than the N-terminal half.




FIGURE 2: Uptake of CCK-8 by HEK293 cells transfected with OATP1B1, 1B3, and chimeras T1–6 and T7–12. Uptake of 0.1 μ M CCK-8 was assessed at 37 °C for 1 min with empty vector and OATP-expressing HEK293 cells. The net uptakes were obtained by subtracting the uptake of cells transfected with empty vector from the uptake of OATP-expressing cells. Final results were obtained by normalizing net uptakes to the surface expression levels of the respective proteins. Values were calculated as picomoles/(milligrams of total protein \times normalization ratio)/minute, where normalization ratio is the surface expression level_{mutant}/surface expression level_{OATP1B3}. Asterisks indicate a $p < 0.05$ level of significant difference from OATP1B3.

Twelve Chimeric Transporters Derived from OATP1B3 and Their Transport Function. To determine which TM(s) is critical for the function of OATP1B3, we constructed 12 chimeras of OATP1B3 (chimeras 1B3_T1, 1B3_T2, 1B3_T3, 1B3_T4, 1B3_T5, 1B3_T6, 1B3_T7, 1B3_T8, 1B3_T9, 1B3_T10, 1B3_T11, and 1B3_T12) by replacing each TM together with the loop preceding it with the corresponding region of OATP1B1 (Figure 3).

Surface biotinylation and Western blot experiments showed that all 12 chimeric transporters were properly expressed on the cell surface (data not shown). Figure 4 summarizes CCK-8 transport of the 12 chimeric transporters together with OATP1B1 and 1B3 after correction for surface expression. Transport mediated by chimeras 1B3_T1, 1B3_T2, 1B3_T4, 1B3_T6, 1B3_T8, 1B3_T9, 1B3_T10, 1B3_T11, and 1B3_T12 was reduced by 30–90% as compared to that of OATP1B3, while transport mediated by chimeras 1B3_T3 and 1B3_T5 was similar to that of OATP1B3. Chimera 1B3_T7 showed a small increased level of transport in comparison with OATP1B3. We observed the greatest reduction for chimera 1B3_T10, whose activity was only 10% of that of OATP1B3. This suggests that the region of TM10 and extracellular loop 5 (EL5) is crucial for normal CCK-8 transport mediated by OATP1B3.

Chimeras 1B3_EL5 and 1B3_TM10 and Their Transport Function. To narrow the region of importance, we constructed two additional chimeras, 1B3_EL5 and 1B3_TM10. Chimera 1B3_EL5 was obtained by replacing EL5 (residues 433–527) of OATP1B3 with that of 1B1, and chimera 1B3_TM10 was obtained by replacing TM10 (residues 528–560) of OATP1B3 with that of 1B1 (Figure 5A). As shown in Figure 5B, chimera 1B3_EL5 maintained 88% transport activity of OATP1B3. In contrast, transport mediated by chimera 1B3_TM10 was reduced to 16% of the transport observed with OATP1B3, which is very similar to the transport of chimera 1B3_T10 (10% of that of OATP1B3).




FIGURE 3: Schematic representation of 12 human OATP1B3-derived chimeric transporters. The chimeric transporters were constructed by replacing each TM domain together with the loop preceding it with its corresponding region of OATP1B1. The replaced residues for each chimera are as follows: residues 1–48 for chimera 1B3_T1, residues 49–88 for 1B3_T2, residues 89–120 for 1B3_T3, residues 121–200 for 1B3_T4, residues 201–230 for 1B3_T5, residues 231–279 for 1B3_T6, residues 280–358 for 1B3_T7, residues 359–394 for 1B3_T8, residues 395–432 for 1B3_T9, residues 433–560 for 1B3_T10, residues 561–595 for 1B3_T11, and residues 596–691 for 1B3_T12.

These results indicate that amino acid residues within TM10 (residues 528–560) but not EL5 are important for CCK-8 transport mediated by OATP1B3.

Sequence Alignment of TM10 and Site-Directed Mutagenesis. Amino acid sequence alignment between OATP1B1 and 1B3 showed that there are 14 residues that differ in TM10 between the two transporters (Figure 6A). To determine which of these 14 amino acid residues would be important for CCK-8 transport of OATP1B3, we produced 14 single-point mutants by replacing each residue in OATP1B3 with its corresponding residue in OATP1B1. All 14 mutants were expressed in HEK293 cells along with OATP1B3 and 1B1; surface expression and CCK-8 uptake were determined, and the data are summarized in Figure 6B. We observed the greatest reduction in transport activity for mutants Y537F (58% of that of OATP1B3), S545L (48% of that of OATP1B3), T550L (57% of that of OATP1B3), and T554S (60% of that of OATP1B3). On the basis of these results, we constructed double mutants Y537F/S545L and S545L/T550L and triple mutants Y537F/S545L/T550L and S545L/T550L/T554S and measured their transport activity (Figure




FIGURE 4: Uptake of CCK-8 by HEK293 cells transfected with OATP1B1, 1B3, and chimeras 1B3_T1, 1B3_T2, 1B3_T3, 1B3_T4, 1B3_T5, 1B3_T6, 1B3_T7, 1B3_T8, 1B3_T9, 1B3_T10, 1B3_T11, and 1B3_T12. Uptake of 0.1 μ M CCK-8 was measured at 37 °C for 1 min with empty vector and OATP-expressing HEK293 cells. The net uptakes were obtained by subtracting the uptake of cells transfected with empty vector from the uptake of OATP-expressing cells. Final results were obtained by normalizing net uptakes to the surface expression levels of the respective proteins. Asterisks indicate a $p < 0.05$ level of significant difference from OATP1B3.

6B). All double and triple mutants showed lower transport activity than single mutants. The triple mutant Y537F/S545L/T550L had the lowest transport activity (22% of that of OATP1B3), similar to that of mutant 1B3_TM10 where the whole TM10 was replaced (Figure 5B, 16% of that of OATP1B3).

Kinetic Studies of CCK-8 Transport by OATP1B3, Chimera 1B3_TM10, and Triple Mutant Y537F/S545L/T550L. Kinetics of CCK-8 transport were analyzed with different constructs. The obtained K_m and V_{max} values for OATP1B3, chimera 1B3_TM10, and the triple mutant Y537F/S545L/T550L are summarized in Table 1. OATP1B3 transported CCK-8 with an apparent K_m of 16.3 μ M and a V_{max} of 495.5 pmol (normalized mg) $^{-1}$ min $^{-1}$. Both chimera 1B3_TM10 and the triple mutant Y537F/S545L/T550L transported CCK-8 with dramatically decreased V_{max} values of 13.3 and 19.0 pmol (normalized mg) $^{-1}$ min $^{-1}$, respectively. Their apparent K_m values also decreased from 16.3 μ M to 1.3 μ M for 1B3_TM10 and to 1.1 μ M for the triple mutant Y537F/S545L/T550L. The overall transport efficiency characterized by V_{max}/K_m of OATP1B3 was decreased from 30.4 to 10.2 for 1B3_TM10 and to 17.3 for the triple mutant Y537F/S545L/T550L. These results suggest that the reduced CCK-8 transport activity of chimera 1B3_TM10 and of the triple mutant Y537F/S545L/T550L is mainly due to a reduction in V_{max} .

Structural Model of the OATP1B3–CCK-8 Complex and the Interactions between Them. Due to the lack of crystal structures with sequences highly similar to that of OATP1B3, we used the fold recognition method incorporated in mGenTHREADER (16) which can detect similarities between three-dimensional structures that are not accompanied by significant sequence similarity to identify the template protein(s). Two proteins, glycerol 3-phosphate transporter GlpT (PDB entry

1PW4) (22) and multidrug transporter EmrD (PDB entry 2GFP) (23), were identified by mGenTHREADER with the highest scores. Both of them belong to the major facilitator superfamily (24), but unlike EmrD which, like OATP1B3, can transport a broad range of hydrophobic compounds, GlpT has a relatively narrow range of structurally related mainly hydrophilic substrates (23). Therefore, we selected EmrD as the template to model the structure of OATP1B3. The generated model was verified using the Prostat module of InsightII which shows that almost all values of the bond lengths, angles, and torsions of the model are tolerable. Procheck was used to calculate the ϕ and ψ angles. The percentage of residues within allowed regions in the Ramachandran plot was 94.7%. These results indicate that the model for OATP1B3 is structurally feasible.

Transmembrane domains 1, 2, 4, 5, 7, 8, 10, and 11 of EmrD form the internal cavity that probably contains the substrate binding site or translocation pathway (23). Because this structure might reflect a general structure of multispecific transporters of the major facilitator superfamily (23), we used AutoDock 3.0 to dock CCK-8 to this internal cavity, and Figure 7 shows the resulting OATP1B3–CCK-8 complex. The OATP1B3 model has 12 TMs with a large extracellular loop between TMs 9 and 10. The putative translocation pathway is formed by TMs 1, 2, 4, 5, 7, 8, 10, and 11, and CCK-8 is located in the middle of the translocation pathway. The side chains of Y537 and S545 in TM10 are facing toward the translocation pathway and might form hydrogen bonds with CCK-8, whereas T550 is located on the other side of TM10 far from the pathway. Besides Y537 and S545, three additional residues, namely, G184 in TM4, Y358 in TM7, and S548 in TM10 which are conserved between OATP1B3 and 1B1, could form hydrogen bonds with CCK-8. OATP1B3 also forms extensive hydrophobic interactions with CCK-8 (Figure 8). The estimated binding free energy ($\Delta G_{binding}$) between CCK-8 and OATP1B3 was calculated using AutoDock3.0 to be -9.66 kcal/mol. The $\Delta G_{binding}$ between CCK-8 and triple mutant Y537F/S545L/T550L was also estimated to be -5.41 kcal/mol. These binding free energies are in good agreement with the respective K_m values of the proteins.

DISCUSSION

OATP1B3 and OATP1B1 are highly homologous proteins and share numerous substrates. However, CCK-8 is an OATP1B3-specific substrate. To determine which regions and residues are essential for OATP1B3-mediated CCK-8 transport, we constructed chimeric proteins between OATP1B3 and 1B1 and used site-directed mutagenesis to change individual amino acid residues in OATP1B3 to the corresponding residues in OATP1B1. Our results show that TM10, which is located in the C-terminal half of OATP1B3, is critical for CCK-8 transport. Furthermore, we have identified three amino acid residues in TM10, namely, Y537, S545, and T550, that appear to be the most important residues for CCK-8 transport among the 14 different residues between OATP1B3 and 1B1 in this region. Triple mutation of these three residues impairs OATP1B3-mediated CCK-8 transport nearly as strongly as the whole TM10 mutation and results in almost identical kinetics. Molecular simulation predicts that TM10 contributes three of five hydrogen bond interactions with CCK-8 (formed by Y537, S545, and S548),




FIGURE 5: Schematic representation of the chimeric transporters 1B3_EL5 and 1B3_TM10 and CCK-8 uptake of the constructs. (A) Chimeras 1B3_EL5 and 1B3_TM10 were constructed by replacing extracellular loop 5 (residues 433–527) and transmembrane domain 10 (residues 528–560) of OATP1B3 with their counterparts from OATP1B1. (B) Uptake of 0.1 μ M CCK-8 was measured with OATP1B1, 1B3, and chimeras 1B3_T10, 1B3_EL5, and 1B3_TM10 in transfected HEK293 cells for 1 min at 37 $^{\circ}$ C. Asterisks indicate a $p < 0.05$ level of significant difference from OATP1B3.




FIGURE 6: Sequence alignment of TM10 and uptake of CCK-8 by mutant OATP1B3. (A) Residues 528–560 of OATP1B1 and 1B3 were aligned, and 14 amino acids were identified as being different between OATP1B3 and 1B1 in this domain: (1B3)N528D(1B1), T529A, F535Y, I536F, Y537F, I543L, S545L, L546F, T550L, T554S, F555H, I556V, L557M, and T559I. (B) Uptake of 0.1 μ M CCK-8 by OATP1B1, 1B3, 14 OATP1B3 single-point mutants, the Y537F/S545L and S545L/T550L double mutants, and Y537F/S545L/T550L and S545L/T550L/T554S triple mutants in TM10 was measured at 37 $^{\circ}$ C for 1 min with empty vector and OATP-expressing HEK293 cells. The net uptakes were obtained by subtracting the uptake of cells transfected with empty vector from the uptake of OATP-expressing cells. Final results were obtained by normalizing net uptakes to the surface expression levels of the respective proteins. Asterisks indicate a $p < 0.05$ level of significant difference from OATP1B3.

Table 1: Kinetic Parameters of CCK-8 Transport Mediated by OATP1B3, Chimera 1B3_TM10, and Triple Mutant Y537F/S545L/T550L

	K_m (μ M)	V_{max} [pmol (normalized mg) $^{-1}$ min $^{-1}$]	V_{max}/K_m
OATP1B3	16.3 \pm 2.4	495.5 \pm 28.7	30.4
Chimera 1B3_TM10	1.3 \pm 0.1	13.3 \pm 0.3	10.2
Triple mutant Y537F/ S545L/T550L	1.1 \pm 0.1	19.0 \pm 0.2	17.3

emphasizing its important role in CCK-8 binding and translocation.

Our observation that chimera T1–6 lost almost all of its OATP1B3-mediated CCK-8 transport while chimera T7–12 maintained some of its activity (Figure 2) provides strong evidence that the C-terminal half of OATP1B3 contains the key domains for CCK-8 recognition and translocation. This conclusion is further supported by the results with the single TM replacements which demonstrate that chimera 1B3_T10 compromises CCK-8 transport function most dramatically (Figure 4). Evidence of the importance of TM10 in other OATPs has already been published. Pucci et al. (25) have reported that the C-terminal domain of the human prostaglandin transporter hPGT (OATP2A1) determines its binding affinity for prostaglandin E2. On the basis of cysteine-scanning mutagenesis, Chan et al. (26) proposed that TM10 of rat PGT forms part of its substrate-binding site. Pharmacogenetic studies demonstrated that patients with a nonsynonymous polymorphism which results in the L543W mutation located in TM10 of OATP1B1 have a higher risk of pravastatin- or atorvastatin-induced myopathy (27). Finally, preliminary results from our laboratory indicate that this region is also critical for OATP1B1-mediated transport. Therefore, we conclude that TM10 might also be important for the function of other OATP family members.

Besides human OATP1B3, the liver-specific rat *Oatp1b2* also transports CCK-8, whereas *Oatp1a1*, *Oatp1a4*, and




FIGURE 7: Three-dimensional model of the OATP1B3-CCK-8 complex. A side view (A) and a view from the intracellular side (B) are presented. Helical segments of the protein are shown as cylinders; the three residues, Y537, S545, and T550, in TM10 are shown in ball-and-stick format and colored orange. CCK-8 is shown in ball-and-stick format and colored purple. CCK-8 is located in the putative translocation pathway which is formed by TMs 1, 2, 4, 5, 7, 8, 10, and 11. The side chains of Y537 and S545 are located on one side of TM10 facing toward the translocation pathway, while T550 is located on the other side of TM10.




FIGURE 8: Schematic representations of hydrogen bond and hydrophobic interactions between CCK-8 and OATP1B3. Dashed lines represent hydrogen bonds between OATP1B3 and CCK-8, and spikes represent residues from OATP1B3 involved in hydrophobic contacts with CCK-8. This figure was made with Ligplot (21).

Oatp1a5 do not show any measurable uptake (11). Sequence alignment analysis of the members of the OATP1 family shows that Y537 is conserved between OATP1B3 and both rat and mouse Oatp1b2 but replaced with a phenylalanine in all other OATP1 family members. This provides additional evidence of the importance of Y537 for CCK-8 transport. Serine at position 545 is also conserved between OATP1B3 and Oatp1b2 but is also found in several other OATP1 family members. These two residues might be important in forming

hydrogen bonds with CCK-8 according to our molecular simulation results (Figure 8).

Mutations and polymorphisms can affect the activity of transporters by various mechanisms such as impairing their membrane localization, changing their binding affinity for substrates, and altering their translocation capacity. In this study, all constructs were expressed on the plasma membrane, their expression levels were measured by surface biotinylation and Western blot analysis, and transport was corrected for surface expression. Hence, altered transport activities of the different chimeras investigated in this study reflect alteration of transport kinetics and not alterations of expression. Therefore, the dramatically reduced V_{\max} values of chimera 1B3_TM10 and of the triple mutant Y537F/S545L/T550L as compared to OATP1B3 (Table 1) suggest that the translocation capacity of OATP1B3 is greatly affected when TM10 or some of the amino acid residues in this region are changed.

To examine whether TM10 is also important for the transport of other substrates, we tested OATP1B3- and chimera 1B3_TM10-mediated uptake of [D-penicillamine^{2,5}]-enkephalin (DPDPE) and taurocholate. At low concentrations, both of them exhibit greater transport in OATP1B3-expressing than in OATP1B1-expressing HEK293 cells. Chimera 1B3_TM10 which does not transport CCK-8 (Figure 4) transports DPDPE to the same level of OATP1B3. Surprisingly, chimera 1B3_TM10 even exhibited increased taurocholate transport activity (data not shown). Thus, TM10 of OATP1B3 might play different roles in the transport of different substrates. Docking studies indicate that DPDPE forms a hydrogen bond with S548 and taurocholate forms a hydrogen bond with N544. Both S548 and N544 are conserved between OATP1B1 and 1B3. A similar phenomenon was described for a point mutation in TM11 of OATP1B3. When stably expressed in HEK293 cells, OATP1B3 with a glycine to glutamate mutation at position 583 showed partial transport activity for BSP and CCK-8, but no transport for estradiol 17 β -glucuronide and dehy-

droepiandrosterone 3-sulfate (DHEAS) (28). One possible explanation might be that due to their structural diversity, different substrates interact with OATP1B3 through different residues in the substrate binding site. Furthermore, our previous studies of the interactions of clotrimazole with OATP1B3 indicated that OATP1B3 has distinct binding sites for its substrate estradiol 17 β -glucuronide and clotrimazole, since clotrimazole can stimulate OATP1B3-mediated estradiol 17 β -glucuronide transport (29). The molecular determinants for OATP1B3-mediated transport of other substrates remain to be elucidated.

In conclusion, our studies reveal that TM10 and in particular the three amino acid residues, Y537, S545, and T550, are key structural and molecular elements for the transport of CCK-8 by OATP1B3. This information should be valuable for the elucidation of the structure–function relationship of OATP1B3.

ACKNOWLEDGMENT

We thank Dr. Bao Ting Zhu for sharing his computational resources with us.

REFERENCES

- Hediger, M. A., Romero, M. F., Peng, J. B., Rolfs, A., Takana, H., and Bruford, E. A. (2004) The ABCs of solute carriers: Physiological, pathological and therapeutic implications of human membrane transport proteins. *Pfluegers Arch.* 447, 465–468.
- Hagenbuch, B., and Meier, P. J. (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. *Pfluegers Arch.* 447, 653–665.
- Hagenbuch, B., and Meier, P. J. (2003) The superfamily of organic anion transporting polypeptides. *Biochim. Biophys. Acta* 1609, 1–18.
- König, J., Seithel, A., Gradhand, U., and Fromm, M. F. (2006) Pharmacogenomics of human OATP transporters. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 372, 432–443.
- Abe, T., Kakyo, M., Tokui, T., Nakagomi, R., Nishio, T., Nakai, D., Nomura, H., Unno, M., Suzuki, M., Naitoh, T., Matsuno, S., and Yawo, H. (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. *J. Biol. Chem.* 274, 17159–17163.
- Abe, T., Unno, M., Onoogawa, T., Tokui, T., Kondo, T. N., Nakagomi, R., Adachi, H., Fujiwara, K., Okabe, M., Suzuki, T., Nunoki, K., Sato, E., Kakyo, M., Nishio, T., Sugita, J., Asano, N., Tanemoto, M., Seki, M., Date, F., Ono, K., Kondo, Y., Shiiba, K., Suzuki, M., Ohtani, H., Shimosegawa, T., Iinuma, Nagura, H., Ito, S., and Matsuno, S. (2001) LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. *Gastroenterology* 120, 1689–1699.
- Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., and Kirchgessner, T. G. (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). *J. Biol. Chem.* 274, 37161–37168.
- König, J., Cui, Y., Nies, A. T., and Keppler, D. (2000) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. *Am. J. Physiol.* 278, G156–G164.
- König, J., Cui, Y., Nies, A. T., and Keppler, D. (2000) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. *J. Biol. Chem.* 275, 23161–23168.
- Wang, P., Hata, S., Xiao, Y., Murray, J. W., and Wolkoff, A. W. (2008) Topological assessment of oatp1a1: A 12-transmembrane domain integral membrane protein with three N-linked carbohydrate chains. *Am. J. Physiol.* 294, G1052–G1059.
- Ismair, M. G., Stieger, B., Cattori, V., Hagenbuch, B., Fried, M., Meier, P. J., and Kullak-Ublick, G. A. (2001) Hepatic uptake of cholecystikinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. *Gastroenterology* 121, 1185–1190.
- Smith, N. F., Acharya, M. R., Desai, N., Figg, W. D., and Sparreboom, A. (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. *Cancer Biol. Ther.* 4, 815–818.
- Kullak-Ublick, G. A., Ismail, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J., and Hagenbuch, B. (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. *Gastroenterology* 120, 525–533.
- Tirona, R. G., Leake, B. F., Merino, G., and Kim, R. B. (2001) Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. *J. Biol. Chem.* 276, 35669–35675.
- Smith, N. F., Marsh, S., Scott-Horton, T. J., Hamada, A., Mielke, S., Mross, K., Figg, W. D., Verweij, J., McLeod, H. L., and Sparreboom, A. (2007) Variants in the SLCO1B3 gene: Interethnic distribution and association with paclitaxel pharmacokinetics. *Clin. Pharmacol. Ther.* 81, 76–82.
- McGuffin, L. J., Bryson, K., and Jones, D. T. (2000) The PSIPRED protein structure prediction server. *Bioinformatics* 16, 404–405.
- Accelrys (2005) *InsightII*, version 2005, Molecular Simulations Inc., San Diego.
- Laskowski, R. A., Macarthur, M. W., Moss, D. S., and Thornton, J. M. (1993) Procheck: A Program to Check the Stereochemical Quality of Protein Structures. *J. Appl. Crystallogr.* 26, 283–291.
- Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., and Olson, A. J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J. Comput. Chem.* 19, 1639–1662.
- Tripos (2005) *Sybyl*, version 7.1, Tripos, St. Louis.
- Wallace, A. C., Laskowski, R. A., and Thornton, J. M. (1995) LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. *Protein Eng.* 8, 127–134.
- Huang, Y., Lemieux, M. J., Song, J., Auer, M., and Wang, D. N. (2003) Structure and mechanism of the glycerol-3-phosphate transporter from *Escherichia coli*. *Science* 301, 616–620.
- Yin, Y., He, X., Szewczyk, P., Nguyen, T., and Chang, G. (2006) Structure of the multidrug transporter EmrD from *Escherichia coli*. *Science* 312, 741–744.
- Pao, S. S., Paulsen, I. T., and Saier, M. H., Jr. (1998) Major facilitator superfamily. *Microbiol. Mol. Biol. Rev.* 62, 1–34.
- Pucci, M. L., Bao, Y., Chan, B., Itoh, S., Lu, R., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Schuster, V. L. (1999) Cloning of mouse prostaglandin transporter PGT cDNA: Species-specific substrate affinities. *Am. J. Physiol.* 279, R734–R741.
- Chan, B. S., Satriano, J. A., and Schuster, V. L. (1999) Mapping the substrate binding site of the prostaglandin transporter PGT by cysteine scanning mutagenesis. *J. Biol. Chem.* 274, 25564–25570.
- Morimoto, K., Oishi, T., Ueda, S., Ueda, M., Hosokawa, M., and Chiba, K. (2004) A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. *Drug Metab. Pharmacokinet.* 19, 453–455.
- Letschert, K., Keppler, D., and König, J. (2004) Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). *Pharmacogenetics* 14, 441–452.
- Gui, C., Miao, Y., Thompson, L., Wahlgren, B., Mock, M., Stieger, B., and Hagenbuch, B. (2008) Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. *Eur. J. Pharmacol.* 584, 57–65.